Eagle Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Eagle Pharmaceuticals Inc cash flow-to-debt ratio. Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow-to-Debt Ratio of 0.00x as of June 2023, meaning its operating cash flow of $-126.00K could theoretically repay 0% of its total liabilities ($152.78 Million) in one year. Check how aggressively does Eagle Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Eagle Pharmaceuticals Inc (2012–2022)
Cash flow-to-debt ratio of Eagle Pharmaceuticals Inc from 2012 to 2022. Historical debt coverage capacity for Eagle Pharmaceuticals Inc across 11 annual periods. Check EGRX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Eagle Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2012–2022)
Eagle Pharmaceuticals Inc cash flow-to-debt ratio by year from 2012 to 2022. Year-by-year debt coverage analysis for Eagle Pharmaceuticals Inc. For the full cash flow conversion analysis, see EGRX cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2022 | 0.18x | $30.80 Million | $172.60 Million | ▼ -51.1% |
| 2021 | 0.37x | $28.22 Million | $77.28 Million | ▼ -50.4% |
| 2020 | 0.74x | $49.50 Million | $67.18 Million | ▼ -0.8% |
| 2019 | 0.74x | $55.99 Million | $75.38 Million | ▲ +10.4% |
| 2018 | 0.67x | $52.38 Million | $77.84 Million | ▲ +3.8% |
| 2017 | 0.65x | $58.92 Million | $90.92 Million | ▼ -24.1% |
| 2016 | 0.85x | $53.21 Million | $62.34 Million | ▲ +400.9% |
| 2015 | -0.28x | $-9.72 Million | $34.26 Million | ▲ +58.4% |
| 2014 | -0.68x | $-13.84 Million | $20.32 Million | ▼ -86.0% |
| 2013 | -0.37x | $-5.88 Million | $16.05 Million | ▲ +49.3% |
| 2012 | -0.72x | $-15.55 Million | $21.54 Million | — |